OncoMatch/Clinical Trials/NCT07108309
BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer
Is NCT07108309 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including BCD-236 and Chemotherapy for triple negative breast cancer.
Treatment: BCD-236 · Chemotherapy — To study the efficacy, safety, pharmacokinetics and immunogenicity of BCD-236 in combination with chemotherapeutic agents (CHT) in 2nd and subsequent lines of therapy of subjects with relapsed and/or metastatic triple negative breast cancer (TNBC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Required: ESR1 expression 0-2 points or <1% (0-2 points or <1%)
ER 0-2 points, PR 0-2 points or ER <1%, PR <1% (ASCO/CAP)
Required: PR (PGR) expression 0-2 points or <1% (0-2 points or <1%)
ER 0-2 points, PR 0-2 points or ER <1%, PR <1% (ASCO/CAP)
Required: HER2 (ERBB2) expression ≤1+ or 2+ without amplification (≤1+ or 2+ without amplification)
HER2 (≤1+) or HER2 (2+) in the absence of amplification of the Her-2-neu gene by ISH
Required: AXL expression (confirmed by immunohistochemistry)
Confirmed AXL expression in tumor cells according to immunohistochemistry
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy — locally advanced unresectable or metastatic TNBC
TNBC is progressive or relapsing on or after systemic therapy. The subject received at least 1 line of systemic therapy for locally advanced unresectable or metastatic TNBC, or she experienced a relapse / progressive disease during or within 6 months after completion of post-operative (adjuvant) chemotherapy.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify